Natera (NASDAQ:NTRA) announced its quarterly earnings data on Thursday. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03), Briefing.com reports. The firm had revenue of $65.30 million for the quarter, compared to analyst estimates of $66.42 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The company’s quarterly revenue was up 16.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.51) earnings per share. Natera updated its FY 2018 guidance to EPS.
Shares of NTRA stock traded down $3.83 on Friday, reaching $16.80. The company had a trading volume of 4,391,474 shares, compared to its average volume of 457,138. The stock has a market capitalization of $1.30 billion, a P/E ratio of -7.00 and a beta of 2.11. Natera has a one year low of $8.60 and a one year high of $29.62.
A number of equities research analysts have issued reports on NTRA shares. JPMorgan Chase & Co. started coverage on shares of Natera in a research note on Friday, October 5th. They set a “neutral” rating and a $26.00 price objective on the stock. Morgan Stanley increased their price objective on shares of Natera from $21.00 to $41.00 and gave the stock an “overweight” rating in a research note on Friday, September 28th. Canaccord Genuity increased their price objective on shares of Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 16th. BidaskClub downgraded shares of Natera from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. Finally, Zacks Investment Research upgraded shares of Natera from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Tuesday, July 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $28.25.
Hedge funds have recently bought and sold shares of the company. Prescott Group Capital Management L.L.C. raised its holdings in Natera by 309.3% in the 3rd quarter. Prescott Group Capital Management L.L.C. now owns 124,428 shares of the medical research company’s stock valued at $2,979,000 after buying an additional 94,028 shares during the last quarter. Harvard Management Co. Inc. bought a new position in Natera in the 3rd quarter valued at approximately $15,297,000. FMR LLC bought a new position in Natera in the 3rd quarter valued at approximately $59,599,000. BlackRock Inc. raised its holdings in Natera by 33.5% in the 3rd quarter. BlackRock Inc. now owns 2,785,208 shares of the medical research company’s stock valued at $66,679,000 after buying an additional 698,379 shares during the last quarter. Finally, Alliancebernstein L.P. raised its holdings in Natera by 7.3% in the 3rd quarter. Alliancebernstein L.P. now owns 41,000 shares of the medical research company’s stock valued at $982,000 after buying an additional 2,800 shares during the last quarter. 67.46% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Natera (NTRA) Announces Earnings Results” was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/11/10/natera-ntra-announces-earnings-results/2973733.html.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.